Glaxo Wellcome has received its first approval, from the UK'sMedicines Control Agency, to market Seretide (fluticasone propionate and salmeterol xinafoate) in a metered dose inhaler. The product was launched last year in the dry powder Diskus inhaler formulation. The company says that while "Seretide has already enjoyed notable commercial success....the MDI, used by 70% of patients worldwide, remains the mainstay of asthma treatment." The UK will now act as reference member state for European Union approval.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze